Skip to main content
Erschienen in: Quality of Life Research 10/2018

19.06.2018

Association between quality of life and clinical characteristics in patients with morphea

verfasst von: G. Bali, S. Kárpáti, M. Sárdy, V. Brodszky, B. Hidvégi, F. Rencz

Erschienen in: Quality of Life Research | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Morphea can lead to considerable cosmetic or functional impairment; nevertheless, health-related quality of life (HRQoL) is rarely documented in adult morphea patients.

Objective

To investigate the impact of morphea on HRQoL and to identify determinants of impaired HRQoL.

Methods

A cross-sectional study has been carried out among adult morphea patients. HRQoL was evaluated by the Dermatology Life Quality Index (DLQI). The modified Localised Scleroderma Skin Severity Index (mLoSSI) and the Localised Scleroderma Damage Index (LoSDI) were applied to evaluate disease activity and damage, respectively. Physician Global Assessment of Activity and Damage (PGA-A, PGA-D) were also completed. Determinants of HRQoL were analysed by multiple regression.

Results

A total of 101 patients (84% females) entered the study, with a mean age of 56.8 ± 14.8 years. Median mLoSSI, LoSDI, PGA-A and PGA-D scores were 8, 5, 9 and 9 points, respectively. Patients with generalised localised (51%) and plaque-type morphea (45%) had median total DLQI scores of 4 and 1, respectively. Embarrassment (53%), itchy or painful skin (46%), and clothing issues (43%) were the most commonly reported problems in the DLQI. Female gender, generalised morphea, higher disease activity (PGA-A score) and involvement of hands and/or feet were significant predictors of impaired HRQoL (p < 0.05).

Conclusion

This study represents the largest sample of adult morphea patients surveyed about their HRQoL in Europe. The frequent occurrence of embarrassment warrants an increased attention to improve patients’ mental health. Care must be taken in case of involvement of functionally sensitive areas, as these cases might require more intensive treatment.
Literatur
1.
Zurück zum Zitat Silman, A., Jannini, S., Symmons, D., & Bacon, P. (1988). An epidemiological study of scleroderma in the West Midlands. British Journal of Rheumatology, 27(4), 286–290.CrossRefPubMed Silman, A., Jannini, S., Symmons, D., & Bacon, P. (1988). An epidemiological study of scleroderma in the West Midlands. British Journal of Rheumatology, 27(4), 286–290.CrossRefPubMed
2.
Zurück zum Zitat Peterson, L. S., Nelson, A. M., Su, W. P., Mason, T., O’Fallon, W. M., & Gabriel, S. E. (1997). The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. Journal of Rheumatology, 24(1), 73–80.PubMed Peterson, L. S., Nelson, A. M., Su, W. P., Mason, T., O’Fallon, W. M., & Gabriel, S. E. (1997). The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. Journal of Rheumatology, 24(1), 73–80.PubMed
3.
Zurück zum Zitat Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., et al. (2017). European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology, 31(9), 1401–1424.CrossRefPubMed Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., et al. (2017). European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology, 31(9), 1401–1424.CrossRefPubMed
4.
Zurück zum Zitat Das, S., Bernstein, I., & Jacobe, H. (2014). Correlates of self-reported quality of life in adults and children with morphea. Journal of the American Academy of Dermatology, 70(5), 904–910.CrossRefPubMedPubMedCentral Das, S., Bernstein, I., & Jacobe, H. (2014). Correlates of self-reported quality of life in adults and children with morphea. Journal of the American Academy of Dermatology, 70(5), 904–910.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Tollefson, M. M., & Witman, P. M. (2007). En coup de sabre morphea and Parry-Romberg syndrome: A retrospective review of 54 patients. Journal of the American Academy of Dermatology, 56(2), 257–263.CrossRefPubMed Tollefson, M. M., & Witman, P. M. (2007). En coup de sabre morphea and Parry-Romberg syndrome: A retrospective review of 54 patients. Journal of the American Academy of Dermatology, 56(2), 257–263.CrossRefPubMed
6.
Zurück zum Zitat Bielsa, I., & Ariza, A. (2007). Deep morphea. Seminars in Cutaneous Medicine and Surgery, 26(2), 90–95.CrossRefPubMed Bielsa, I., & Ariza, A. (2007). Deep morphea. Seminars in Cutaneous Medicine and Surgery, 26(2), 90–95.CrossRefPubMed
7.
Zurück zum Zitat Christen-Zaech, S., Hakim, M. D., Afsar, F. S., & Paller, A. S. (2008). Pediatric morphea (localized scleroderma): Review of 136 patients. Journal of the American Academy of Dermatology, 59(3), 385–396.CrossRefPubMed Christen-Zaech, S., Hakim, M. D., Afsar, F. S., & Paller, A. S. (2008). Pediatric morphea (localized scleroderma): Review of 136 patients. Journal of the American Academy of Dermatology, 59(3), 385–396.CrossRefPubMed
8.
Zurück zum Zitat Leitenberger, J. J., Cayce, R. L., Haley, R. W., Adams-Huet, B., Bergstresser, P. R., & Jacobe, H. T. (2009). Distinct autoimmune syndromes in morphea: A review of 245 adult and pediatric cases. Archives of Dermatology, 145(5), 545–550.CrossRefPubMedPubMedCentral Leitenberger, J. J., Cayce, R. L., Haley, R. W., Adams-Huet, B., Bergstresser, P. R., & Jacobe, H. T. (2009). Distinct autoimmune syndromes in morphea: A review of 245 adult and pediatric cases. Archives of Dermatology, 145(5), 545–550.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Mills, S. D., Fox, R. S., & Malcarne, V. L. (2015). Body image in children with morphea: A systematic review. Pediatric Dermatology, 32(4), e188–e190.CrossRefPubMed Mills, S. D., Fox, R. S., & Malcarne, V. L. (2015). Body image in children with morphea: A systematic review. Pediatric Dermatology, 32(4), e188–e190.CrossRefPubMed
10.
Zurück zum Zitat Lis-Swiety, A., Janicka, I., Skrzypek-Salamon, A., & Brzezinska-Wcislo, L. (2017). A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. Journal of the American Academy of Dermatology, 31(1), 30–37.CrossRef Lis-Swiety, A., Janicka, I., Skrzypek-Salamon, A., & Brzezinska-Wcislo, L. (2017). A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. Journal of the American Academy of Dermatology, 31(1), 30–37.CrossRef
11.
Zurück zum Zitat Klimas, N. K., Shedd, A. D., Bernstein, I. H., & Jacobe, H. (2015). Health-related quality of life in morphoea. British Journal of Dermatology, 172(5), 1329–1337.CrossRefPubMed Klimas, N. K., Shedd, A. D., Bernstein, I. H., & Jacobe, H. (2015). Health-related quality of life in morphoea. British Journal of Dermatology, 172(5), 1329–1337.CrossRefPubMed
12.
Zurück zum Zitat Kroft, E. B., de Jong, E. M., & Evers, A. W. (2009). Psychological distress in patients with morphea and eosinophilic fasciitis. Archives of Dermatology, 145(9), 1017–1022.CrossRefPubMed Kroft, E. B., de Jong, E. M., & Evers, A. W. (2009). Psychological distress in patients with morphea and eosinophilic fasciitis. Archives of Dermatology, 145(9), 1017–1022.CrossRefPubMed
13.
Zurück zum Zitat Kroft, E. B., de Jong, E. M., & Evers, A. W. (2008). Physical burden of symptoms in patients with localized scleroderma and eosinophilic fasciitis. Archives of Dermatology, 144(10), 1394–1395.CrossRefPubMed Kroft, E. B., de Jong, E. M., & Evers, A. W. (2008). Physical burden of symptoms in patients with localized scleroderma and eosinophilic fasciitis. Archives of Dermatology, 144(10), 1394–1395.CrossRefPubMed
14.
Zurück zum Zitat Szramka-Pawlak, B., Danczak-Pazdrowska, A., Rzepa, T., Szewczyk, A., Sadowska-Przytocka, A., & Zaba, R. (2014). Quality of life and optimism in patients with morphea. Applied Research in Quality of Life, 9(4), 863–870.CrossRefPubMed Szramka-Pawlak, B., Danczak-Pazdrowska, A., Rzepa, T., Szewczyk, A., Sadowska-Przytocka, A., & Zaba, R. (2014). Quality of life and optimism in patients with morphea. Applied Research in Quality of Life, 9(4), 863–870.CrossRefPubMed
15.
Zurück zum Zitat Szramka-Pawlak, B., Danczak-Pazdrowska, A., Rzepa, T., Szewczyk, A., Sadowska-Przytocka, A., & Zaba, R. (2013). Health-related quality of life, optimism, and coping strategies in persons suffering from localized scleroderma. Psychology, Health & Medicine, 18(6), 654–663.CrossRef Szramka-Pawlak, B., Danczak-Pazdrowska, A., Rzepa, T., Szewczyk, A., Sadowska-Przytocka, A., & Zaba, R. (2013). Health-related quality of life, optimism, and coping strategies in persons suffering from localized scleroderma. Psychology, Health & Medicine, 18(6), 654–663.CrossRef
16.
Zurück zum Zitat Orzechowski, N. M., Davis, D. M., Mason, T. G. 3rd, Crowson, C. S., & Reed, A. M. (2009). Health-related quality of life in children and adolescents with juvenile localized scleroderma. Rheumatology, 48(6), 670–672.CrossRefPubMed Orzechowski, N. M., Davis, D. M., Mason, T. G. 3rd, Crowson, C. S., & Reed, A. M. (2009). Health-related quality of life in children and adolescents with juvenile localized scleroderma. Rheumatology, 48(6), 670–672.CrossRefPubMed
17.
Zurück zum Zitat Mertens, J. S., Thurlings, R. M., Kievit, W., Seyger, M. M. B., Radstake, T. R. D., & de Jong, E. (2017). Long-term outcome of eosinophilic fasciitis: A cross-sectional evaluation of 35 patients. Journal of the American Academy of Dermatology, 77(3), 512–517 e515.CrossRefPubMed Mertens, J. S., Thurlings, R. M., Kievit, W., Seyger, M. M. B., Radstake, T. R. D., & de Jong, E. (2017). Long-term outcome of eosinophilic fasciitis: A cross-sectional evaluation of 35 patients. Journal of the American Academy of Dermatology, 77(3), 512–517 e515.CrossRefPubMed
18.
Zurück zum Zitat van der Linden, M. M., van Rappard, D. C., Daams, J. G., Sprangers, M. A., Spuls, P. I., & de Korte, J. (2015). Health-related quality of life in patients with cutaneous rosacea: A systematic review. Acta Dermato-Venereologica, 95(4), 395–400.CrossRefPubMed van der Linden, M. M., van Rappard, D. C., Daams, J. G., Sprangers, M. A., Spuls, P. I., & de Korte, J. (2015). Health-related quality of life in patients with cutaneous rosacea: A systematic review. Acta Dermato-Venereologica, 95(4), 395–400.CrossRefPubMed
19.
Zurück zum Zitat Gerard, A. J., Feldman, S. R., & Strowd, L. (2015). Quality of life of patients with pyoderma gangrenosum and hidradenitis suppurativa. Journal of Cutaneous Medicine and Surgery, 19(4), 391–396.CrossRefPubMed Gerard, A. J., Feldman, S. R., & Strowd, L. (2015). Quality of life of patients with pyoderma gangrenosum and hidradenitis suppurativa. Journal of Cutaneous Medicine and Surgery, 19(4), 391–396.CrossRefPubMed
20.
Zurück zum Zitat Rencz, F., Gulacsi, L., Pentek, M., Wikonkal, N., Baji, P., & Brodszky, V. (2016). Alopecia areata and health-related quality of life: A systematic review and meta-analysis. British Journal of Dermatology, 175(3), 561–571.CrossRefPubMed Rencz, F., Gulacsi, L., Pentek, M., Wikonkal, N., Baji, P., & Brodszky, V. (2016). Alopecia areata and health-related quality of life: A systematic review and meta-analysis. British Journal of Dermatology, 175(3), 561–571.CrossRefPubMed
21.
Zurück zum Zitat Rencz, F., Gulacsi, L., Tamasi, B., Karpati, S., Pentek, M., Baji, P., et al. (2015). Health-related quality of life and its determinants in pemphigus: A systematic review and meta-analysis. British Journal of Dermatology, 173(4), 1076–1080.CrossRefPubMed Rencz, F., Gulacsi, L., Tamasi, B., Karpati, S., Pentek, M., Baji, P., et al. (2015). Health-related quality of life and its determinants in pemphigus: A systematic review and meta-analysis. British Journal of Dermatology, 173(4), 1076–1080.CrossRefPubMed
22.
Zurück zum Zitat Hill, M. K., Kheirandish Pishkenari, A., Braunberger, T. L., Armstrong, A. W., & Dunnick, C. A. (2016). Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. Journal of the American Academy of Dermatology, 75(5), 906–917.CrossRefPubMed Hill, M. K., Kheirandish Pishkenari, A., Braunberger, T. L., Armstrong, A. W., & Dunnick, C. A. (2016). Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. Journal of the American Academy of Dermatology, 75(5), 906–917.CrossRefPubMed
23.
Zurück zum Zitat Amer, A. A., & Gao, X. H. (2016). Quality of life in patients with vitiligo: An analysis of the dermatology life quality index outcome over the past two decades. International Journal of Dermatology, 55(6), 608–614.CrossRefPubMed Amer, A. A., & Gao, X. H. (2016). Quality of life in patients with vitiligo: An analysis of the dermatology life quality index outcome over the past two decades. International Journal of Dermatology, 55(6), 608–614.CrossRefPubMed
24.
Zurück zum Zitat Gaulin, C., Sebaratnam, D. F., & Fernandez-Penas, P. (2015). Quality of life in non-melanoma skin cancer. Australasian Journal of Dermatology, 56(1), 70–76.CrossRefPubMed Gaulin, C., Sebaratnam, D. F., & Fernandez-Penas, P. (2015). Quality of life in non-melanoma skin cancer. Australasian Journal of Dermatology, 56(1), 70–76.CrossRefPubMed
25.
Zurück zum Zitat Almeida, C., Almeida, I., & Vasconcelos, C. (2015). Quality of life in systemic sclerosis. Autoimmunity Reviews, 14(12), 1087–1096.CrossRefPubMed Almeida, C., Almeida, I., & Vasconcelos, C. (2015). Quality of life in systemic sclerosis. Autoimmunity Reviews, 14(12), 1087–1096.CrossRefPubMed
26.
Zurück zum Zitat Finlay, A. Y., & Khan, G. K. (1994). Dermatology life quality index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.CrossRefPubMed Finlay, A. Y., & Khan, G. K. (1994). Dermatology life quality index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.CrossRefPubMed
27.
Zurück zum Zitat Arkachaisri, T., Vilaiyuk, S., Torok, K. S., & Medsger, T. A. Jr. (2010). Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: A proof-of-concept study. Rheumatology, 49(2), 373–381.CrossRefPubMed Arkachaisri, T., Vilaiyuk, S., Torok, K. S., & Medsger, T. A. Jr. (2010). Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: A proof-of-concept study. Rheumatology, 49(2), 373–381.CrossRefPubMed
28.
Zurück zum Zitat Kelsey, C. E., & Torok, K. S. (2013). The localized scleroderma cutaneous assessment tool: Responsiveness to change in a pediatric clinical population. Journal of the American Academy of Dermatology, 69(2), 214–220.CrossRefPubMedPubMedCentral Kelsey, C. E., & Torok, K. S. (2013). The localized scleroderma cutaneous assessment tool: Responsiveness to change in a pediatric clinical population. Journal of the American Academy of Dermatology, 69(2), 214–220.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Arkachaisri, T., & Pino, S. (2008). Localized scleroderma severity index and global assessments: A pilot study of outcome instruments. The Journal of Rheumatology, 35(4), 650–657.PubMed Arkachaisri, T., & Pino, S. (2008). Localized scleroderma severity index and global assessments: A pilot study of outcome instruments. The Journal of Rheumatology, 35(4), 650–657.PubMed
30.
Zurück zum Zitat Arkachaisri, T., Vilaiyuk, S., Li, S., O’Neil, K. M., Pope, E., Higgins, G. C., et al. (2009). The localized scleroderma skin severity index and physician global assessment of disease activity: A work in progress toward development of localized scleroderma outcome measures. The Journal of Rheumatology, 36(12), 2819–2829.CrossRefPubMedPubMedCentral Arkachaisri, T., Vilaiyuk, S., Li, S., O’Neil, K. M., Pope, E., Higgins, G. C., et al. (2009). The localized scleroderma skin severity index and physician global assessment of disease activity: A work in progress toward development of localized scleroderma outcome measures. The Journal of Rheumatology, 36(12), 2819–2829.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Swinscow, T. D. V., & Campbell, M. J. (2002). Statistics at square one. BMJ: London. Swinscow, T. D. V., & Campbell, M. J. (2002). Statistics at square one. BMJ: London.
32.
Zurück zum Zitat Rencz, F., Poór, A. K., Péntek, M., Holló, P., Kárpáti, S., Gulácsi, L., et al. (2018). A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: Potential biases in treatment decisions. Journal of the European Academy of Dermatology and Venereology, 32(5), 783–790.CrossRefPubMed Rencz, F., Poór, A. K., Péntek, M., Holló, P., Kárpáti, S., Gulácsi, L., et al. (2018). A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: Potential biases in treatment decisions. Journal of the European Academy of Dermatology and Venereology, 32(5), 783–790.CrossRefPubMed
33.
Zurück zum Zitat Ardalan, K., Zigler, C. K., & Torok, K. S. (2017). Predictors of longitudinal quality of life in Juvenile localized Scleroderma. Arthritis Care & Research, 69(7), 1082–1087.CrossRef Ardalan, K., Zigler, C. K., & Torok, K. S. (2017). Predictors of longitudinal quality of life in Juvenile localized Scleroderma. Arthritis Care & Research, 69(7), 1082–1087.CrossRef
34.
Zurück zum Zitat Sampogna, F., Raskovic, D., Guerra, L., Pedicelli, C., Tabolli, S., Leoni, L., et al. (2008). Identification of categories at risk for high quality of life impairment in patients with vitiligo. British Journal of Dermatology, 159(2), 351–359.CrossRefPubMed Sampogna, F., Raskovic, D., Guerra, L., Pedicelli, C., Tabolli, S., Leoni, L., et al. (2008). Identification of categories at risk for high quality of life impairment in patients with vitiligo. British Journal of Dermatology, 159(2), 351–359.CrossRefPubMed
35.
Zurück zum Zitat Heredi, E., Rencz, F., Balogh, O., Gulacsi, L., Herszenyi, K., Hollo, P., et al. (2014). Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: A cross-sectional study in psoriasis from Hungary. The European Journal of Health Economics, 15(Suppl 1), S111–S119.CrossRefPubMed Heredi, E., Rencz, F., Balogh, O., Gulacsi, L., Herszenyi, K., Hollo, P., et al. (2014). Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: A cross-sectional study in psoriasis from Hungary. The European Journal of Health Economics, 15(Suppl 1), S111–S119.CrossRefPubMed
36.
Zurück zum Zitat Ongenae, K., Dierckxsens, L., Brochez, L., van Geel, N., & Naeyaert, J. M. (2005). Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology, 210(4), 279–285.CrossRefPubMed Ongenae, K., Dierckxsens, L., Brochez, L., van Geel, N., & Naeyaert, J. M. (2005). Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology, 210(4), 279–285.CrossRefPubMed
37.
Zurück zum Zitat Schmid-Ott, G., Kuensebeck, H. W., Jaeger, B., Werfel, T., Frahm, K., Ruitman, J., et al. (1999). Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta Dermato-Venereologica, 79(6), 443–447.CrossRefPubMed Schmid-Ott, G., Kuensebeck, H. W., Jaeger, B., Werfel, T., Frahm, K., Ruitman, J., et al. (1999). Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta Dermato-Venereologica, 79(6), 443–447.CrossRefPubMed
38.
Zurück zum Zitat Schmid-Ott, G., Kunsebeck, H. W., Jager, B., Sittig, U., Hofste, N., Ott, R., et al. (2005). Significance of the stigmatization experience of psoriasis patients: A 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Dermato-Venereologica, 85(1), 27–32.CrossRefPubMed Schmid-Ott, G., Kunsebeck, H. W., Jager, B., Sittig, U., Hofste, N., Ott, R., et al. (2005). Significance of the stigmatization experience of psoriasis patients: A 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Dermato-Venereologica, 85(1), 27–32.CrossRefPubMed
39.
Zurück zum Zitat van Beugen, S., van Middendorp, H., Ferwerda, M., Smit, J. V., Zeeuwen-Franssen, M. E., Kroft, E. B., et al. (2017). Predictors of perceived stigmatization in patients with psoriasis. British Journal of Dermatology, 176(3), 687–694.CrossRefPubMed van Beugen, S., van Middendorp, H., Ferwerda, M., Smit, J. V., Zeeuwen-Franssen, M. E., Kroft, E. B., et al. (2017). Predictors of perceived stigmatization in patients with psoriasis. British Journal of Dermatology, 176(3), 687–694.CrossRefPubMed
Metadaten
Titel
Association between quality of life and clinical characteristics in patients with morphea
verfasst von
G. Bali
S. Kárpáti
M. Sárdy
V. Brodszky
B. Hidvégi
F. Rencz
Publikationsdatum
19.06.2018
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 10/2018
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-1897-1

Weitere Artikel der Ausgabe 10/2018

Quality of Life Research 10/2018 Zur Ausgabe